[ Inside the business ]

EW stock analysis

EW · Edwards Lifesciences Corp

Orthopedic, prosthetic and surgical appliances and supplies. Growing 10%. Keeps 22¢ of every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 3.5× sales in 5 yrs. Evidence: sales +10% · 22¢ profit/$1.

01 What's priced in?3.5× sales in 5 yrs
Sales now$6.7B
Needed in 5 yrs$23.6B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +10%, steady
No customer over 10%
Prepaid $13MSales +10%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 22¢ per $1, falling
'21'22'23'24'2522¢
Before running costs: 84% → 78%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −2.0%/yrDebt $599M
07 What could break it?2 to watch
  • Growth slowing
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +17%, +14%, then +10% vs. a year ago. New filings show a new major deal.

What could go wrong

Few warning signs.

It has moved 1.0× the market. In the 2022 rate shock it fell 36% while the market fell 24%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

72% Transcatheter Aortic Valve Replacement.

Transcatheter Aortic Valve Replacement 72% · Surgical 15% · Transcatheter Mitral And Tricuspid Therapies 12% (latest quarter)

Where each dollar goes

22¢ profit.

22¢ to make what it sells, 56¢ on research and overhead, 22¢ left over. Revenue $6.7B in the last 12 months.

Its market

0.6× the economy.

The government expects its industry, converted paper product manufacturing, to grow 1.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 168¢ of each $1 of profit.

Competitive advantage

10 of 10 years.

Returns beat its 8.9% cost of capital in 10 of the last 10 years. Gross margin went from 73% to 78%.

Future bets

16% on research.

$1.1B a year on R&D. $293M on equipment and buildings.

All figures from Edwards Lifesciences Corp's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.